| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $4.5M | 0.01% | 684.70K | +93% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CERT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 31, 2026 | Corcoran DanielleGeneral Counsel | — | 22.8K | — |
| May 31, 2026 | Anhalt RonaOfficer | — | 7.1K | — |
| May 13, 2026 | Reynders John V WChief Financial Officer | — | 15.8K | — |
| May 13, 2026 | Bedi ArjunDirector | — | 5.5K | — |
| May 13, 2026 | Cashman James E IiiChairman of the Board | — | 15.8K | — |
| May 13, 2026 | Broshy EranChairman of the Board | — | 15.8K | — |
| May 13, 2026 | Walsh Matthew MDirector | — | 15.8K | — |
| May 13, 2026 | Collins CynthiaDirector | — | 15.8K | — |
| May 13, 2026 | Crane Rosemary ADirector | — | 15.8K | — |
| May 13, 2026 | Killefer NancyDirector | — | 15.8K | — |
| May 10, 2026 | Resnick Jon MatthewChief Executive Officer | — | 59.8K | — |
| Mar 31, 2026 | Aspbury RobertOfficer | Stock Award(Grant) at price 0.00 per share. | 14.5K | — |
| Mar 31, 2026 | Aspbury RobertOfficer | — | 33.2K | — |
| Mar 31, 2026 | Corcoran DanielleGeneral Counsel | — | 10.8K | — |
| Mar 31, 2026 | Anhalt RonaOfficer | — | 9.8K | — |
| Mar 31, 2026 | Mckemey AdrianOfficer | — | 10.8K | — |
| Mar 31, 2026 | Pedersen Leif EPresident | Stock Award(Grant) at price 0.00 per share. | 14.5K | — |
| Mar 31, 2026 | Pedersen Leif EPresident | — | 33.2K | — |
| Mar 31, 2026 | Gallagher John EChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 23.3K | — |
| Mar 31, 2026 | Gallagher John EChief Financial Officer | — | 50.6K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.2 | -19.5 | -19.5 | 7.5 | -5.1 | 12.5 | 23.7 | 2.3 | 11.0 | 0.4 | +4.9% | ||
| 2025 | 33.6 | -15.8 | -17.4 | 40.0 | -18.0 | 3.0 | -15.9 | 10.2 | 12.7 | -4.8 | -21.2 | -3.8 | −17.3% |
| 2024 | -8.1 | 4.5 | 5.9 | -4.3 | -0.9 | -18.3 | 12.7 | -21.5 | -4.4 | -12.9 | 9.9 | -5.0 | −39.5% |
| 2023 | 20.7 | -6.6 | 33.1 | 0.2 | -14.0 | -12.4 | 6.9 | -17.0 | -10.0 | -16.2 | 18.2 | 22.1 | +9.5% |
| 2022 | -5.9 | -5.2 | -15.2 | -14.6 | 10.7 | 5.6 | 7.1 | -31.8 | -15.3 | -7.9 | 38.8 | -5.4 | −43.5% |
| 2021 | 2.1 | 0.7 | -21.2 | 16.5 | -17.3 | 7.7 | -4.0 | 23.4 | -1.4 | 24.8 | -34.8 | 5.5 | −15.7% |
| 2020 | — |
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Buy / hold / sell counts